News from sanofi A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 06, 2019, 09:25 ET New data to be presented at ASH 2019 highlight Sanofi's commitment to treat challenging blood cancers and rare blood disorders

New clinical data from Sanofi's oncology and rare blood disorders portfolios and pipelines will be featured, including four oral presentations and 18 ...

Nov 04, 2019, 17:30 ET FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older

The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for Fluzone® High-Dose Quadrivalent (Influenza...

Nov 04, 2019, 07:00 ET Positive results in Phase 3 trial for Toujeo® in children and adolescents with type 1 diabetes

Children and adolescents (aged 6 to 17 years) living with type 1 diabetes achieved comparable reduction in average blood sugar (HbA1c) and similar...

Oct 31, 2019, 08:00 ET Sanofi Q3 well on track

Sanofi (NASDAQ: SNY; EURONEXT: SAN) Q3 2019 Change Change at CER 9M 2019 Change Change at CER IFRS net sales reported €9,499m +1.1% -1.1% €26,518m +4....

Oct 18, 2019, 11:00 ET Sanofi to conduct precautionary voluntary recall of Zantac OTC in U.S. and Canada

As a precautionary measure, Sanofi will conduct a voluntary recall of Zantac OTC (over-the-counter) in the U.S. and Canada. This recall is being...

Oct 15, 2019, 08:00 ET Sanofi opens its first digitally-enabled, continuous manufacturing facility; ushers in next generation of biotech manufacturing

Sanofi today celebrates the inauguration of its new digital manufacturing facility in Framingham, Massachusetts, marking one of the world's first...

Sep 30, 2019, 10:30 ET New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic castration-resistant prostate cancer

Data published today in the New England Journal of Medicine showed that patients with metastatic castration-resistant prostate cancer (mCRPC)...

Jul 29, 2019, 08:00 ET Sanofi delivered solid growth in Q2 2019

Sanofi (NASDAQ: SNY; EURONEXT: SAN) Q2 2019 Change Change at CER H1 2019 Change Change at CER IFRS net sales reported €8,628m +5.5% +3.9% €17,019m +5....

Jul 03, 2019, 08:00 ET Easing the Burden for People with Hemophilia

As recently as five years ago, effectively managing hemophilia meant frequent therapy infusions to prevent uncontrolled bleeding, limitations on...

Jun 26, 2019, 13:30 ET FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis

The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for use with other medicines to treat chronic rhinosinusitis with...

May 15, 2019, 17:00 ET Sanofi oncology pipeline targeting various cancers highlighted at ASCO 2019

Sanofi's oncology franchise and robust pipeline will be featured at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, delivering...

May 08, 2019, 13:12 ET Sanofi Recognized by DiversityInc as a Top 50 Company

For the second consecutive year, Sanofi has been named to DiversityInc's 2019 Top 50 Companies for Diversity. The DiversityInc Top 50 list recognizes ...

May 01, 2019, 18:35 ET FDA approves Dengvaxia® for the prevention of dengue in individuals ages 9 through 16 living in U.S. endemic areas

The U.S. Food and Drug Administration (FDA) approved Dengvaxia® (Dengue Tetravalent Vaccine, Live) for the prevention of dengue disease caused by...
Sanofi delivers strong Q1 2019 business EPS growth of 9.4% at CER

Apr 26, 2019, 08:05 ET Sanofi delivers strong Q1 2019 business EPS growth of 9.4% at CER

Sanofi (NASDAQ: SNY; EURONEXT: SAN) Q1 2019 Change Change at CER IFRS net sales reported €8,391m +6.2% +4.2% IFRS net income reported €1,137m +11.9%...

Apr 17, 2019, 10:11 ET Sanofi Named One of America's Best Employers by Forbes

Forbes has named Sanofi one of America's Best Employers. This is the first time Sanofi has appeared on the Forbes list. "It is an amazing...

Apr 17, 2019, 07:00 ET World Hemophilia Day: Sanofi Genzyme Donation Impacts Patients Across the Globe

On World Hemophilia Day April 17th, the global bleeding disorders community unites to raise awareness and understanding of hemophilia and areas of...

Apr 10, 2019, 05:00 ET Sanofi provides unprecedented access to its insulins for one set monthly price

Starting in June, Sanofi will further expand its innovative Insulins Valyou Savings Program so people living with diabetes in the United States can...

Mar 11, 2019, 15:45 ET FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents

The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe...

Feb 27, 2019, 16:17 ET FDA expands indication for Soliqua® 100/33

The U.S. Food and Drug Administration (FDA) has approved the expanded use of Soliqua® 100/33 (insulin glargine and lixisenatide injection) 100...

Feb 11, 2019, 07:00 ET Sanofi and Regeneron offer Praluent® (alirocumab) at a new reduced U.S. list price

Praluent® (alirocumab) will be made available at a new reduced U.S. list price of $5,850 annually, a 60% reduction from the original price, for both...

Feb 07, 2019, 08:00 ET Sanofi delivers 2018 business EPS growth of 5.1% at CER

Sanofi (NASDAQ: SNY; EURONEXT: SAN) Q4 2018 Change Change at CER 2018 Change Change at CER IFRS net sales reported €8,997m +3.5% +3.9% €34,463m -1.7% ...

Feb 06, 2019, 11:53 ET FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)

The U.S. Food and Drug Administration (FDA) has approved Cablivi® (caplacizumab-yhdp) in combination with plasma exchange and immunosuppression for...

Jan 30, 2019, 07:00 ET Sanofi Presents Research Advances in Rare Genetic Diseases at 15th Annual WORLDSymposium™ 2019

Continued research and development is critical to advancing care for people with rare diseases who have a significant need for earlier diagnosis,...

Jan 23, 2019, 14:53 ET FDA approves use of 0.5 mL dose of Fluzone® Quadrivalent (influenza vaccine) in children as young as 6 months of age

The U.S. Food and Drug Administration has approved the use of the 0.5 mL dose of Fluzone® Quadrivalent (influenza vaccine) to include children age 6...

Jan 14, 2019, 16:47 ET FDA Approves Expanded Use of Adacel® (Tdap) Vaccine for Repeat Vaccination

The U.S. Food and Drug Administration has approved the expanded use of Adacel® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis...